Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

National Immunization Strategy 2017-2022


Foreword
 
There have been many transformations to the NIP inthe recent years. New vaccines wereadded to the vaccination schedule, the cohorts served by the public sector kepton expandingsince the onset of the Syrian crisis, measures to consolidatethe vaccine purchasing arrangements were adopted,and there wasa leveraging up ofthe vaccinovigilanceand its effective management.In 2016, the Ministryof health in Lebanon decided that it was the time to take stock, constructon the current NIP strengthsand achievements andidentify areas for further improvement. A strategy for the NIP for 2016-2020 wasenvisagedin agreementwith the development partners. A detailed situation analysis assessment was initiatedin October 2015 in two stages: at the initial stage, the country and health system contexts were analyzed, and immunization system performance was measured. In the second stage, a framework was developed in consultations with key stakeholders to define gaps in the evidence. Immunization coverage evaluation survey was conducted in 2016 and fed into filling the lacunas in information.

The present document expresses the country vision, goals and priorities of the national immunization program. It relies on a careful examination of the situation analysis, an assessment of the enablers and challenges facing the immunization services and defines the national immunization strategies addressing these contests. The strategies were formulated as informed choices across more than one solution deemed most feasible and efficient considering the country context.

The document is structured in three sections:

Section 1“Situational analysis” presents briefly the organization and operation of the national immunization program as well as the recent achievements and remaining challenges,

Section 2 “Conceptual framework” describes the future vision of the country in regards to vaccine preventable diseases, the long term goals to be achieved and the more specific results –immunization system objectives and targets for 2020,

Section 3 defines the Strategies to address the bottlenecks and achieve immunization system objectives by 2020. Most of strategies (so called “immunization system specific” ones) are presented by relevant health system blocks.The focus of the NIP Strategy, is to assistthe MOPH to meet international goals set by the World Health Organization (WHO) under the Global Immunization Vision and Strategy (GIVS). The Strategy articulates action areas to conserve the successful achievements of the last years, built on the current favoring momentum and propose solutions for the drawbacks

The Strategy comprises nineStrategic Priority Areas to complement and strengthen the NIP.

The matrix (Figure 2) in Annexesshows expected results of the immunization system development strategies by health system building blocks and links them to the root causes (weaknesses and treats) identified during the system analysis...
    1
    ...
ATC Name B/G ↓ Ingredients Dosage Form Price
A06AD04 EPSOM SALT G Magnesium sulfate - 40g 40g Granules 89,590 L.L
A10BD20 EMPAZIMET G Metformin HCl - 1000mg, Empagliflozin - 5mg Tablet, film coated 1,840,168 L.L
D07AC13 ELICA G Mometasone furoate - 1mg/g 0.1% Cream 341,336 L.L
D07AC13 ELISONE G Mometasone furoate - 0.1% 0.1% Cream 249,955 L.L
J05AR03 EMZAVIR G Emtricitabine - 200mg, Tenofovir disoproxil fumarate - 300mg Tablet, film coated 18,701,506 L.L
D07AC13 ELISONE G Mometasone furoate - 0.1% 0.1% Cream 435,405 L.L
V03AF03 EUROFOLIC G Folic acid as Calcium Folinate Hydrate - 100mg/10ml 10mg/ml Injectable solution L.L
D07AC13 ELICA G Mometasone furoate micronized - 1mg/g 0.1% Ointment 399,121 L.L
C09BB06 ENEAS G Enalapril maleate - 10mg, Nitrendipine - 20mg Tablet 2,009,045 L.L
M01AB05 EPARDEX G Diclofenac sodium - 50mg 50mg Tablet, enteric coated 223,974 L.L
S01XA18 ESTAPORIN G Ciclosporin - 0.05% 0.05% Emulsion 2,815,798 L.L
J01FA10 ERADECIN G Azithromycin - 250mg 250mg Capsule 354,774 L.L
M01AB05 EPARDEX G Diclofenac sodium - 50mg 50mg Tablet, enteric coated 3,246,979 L.L
B01AF02 ELAPIX 5 G Apixaban - 5mg 5mg Tablet, film coated 1,970,969 L.L
C10AA05 EMITOR G Atorvastatin - 20mg 20mg Tablet, film coated 822,432 L.L
B01AF02 ELAPIX 2.5 G Apixaban - 2.5mg 2.5mg Tablet, film coated 1,970,969 L.L
L01EA02 ELPIDA G Dasatinib - 70mg 70mg Tablet, film coated 127,364,905 L.L
M01AB05 EMIFENAC 50 G Diclofenac sodium - 50mg 50mg Tablet, dispersible 387,027 L.L
L01EA02 ELPIDA G Dasatinib - 50mg 50mg Tablet, film coated 127,364,905 L.L
L01EA02 ELPIDA G Dasatinib - 20mg 20mg Tablet, film coated 103,165,573 L.L
D07XB05 ECOZONE G Dexamethazone sodium phosphate - 0.1%, Econazole nitrate - 1% Cream 364,757 L.L
A07EA06 ENTOCORT CIR G Budesonide - 3mg 3mg Capsule, hard, modified release 7,823,588 L.L
A07EA06 ENTOCORT CIR G Budesonide - 3mg 3mg Capsule, hard, modified release 4,771,985 L.L
D07XC03 ELICA M G Mometasone furoate - 0.1%, Miconazole nitrate - 2% Cream 459,594 L.L
L02BB04 ENZASTIK 40 G Enzalutamide - 40mg 40mg Capsule 82,838,963 L.L
C10AA05 EMITOR G Atorvastatin - 40mg 40mg Tablet, film coated 1,060,292 L.L
D07XC03 ELICASAL G Mometasone furoate - 1mg/g, Salicylic acid - 50mg/g Ointment 462,282 L.L
A10BK03 EMPAZA G Empagliflozin - 25mg 25mg Tablet, film coated 1,740,724 L.L
G04BE08 ENKOR G Tadalafil - 20mg 20mg Tablet, film coated 1,032,839 L.L
A10BK03 EMPAZA G Empagliflozin - 10mg 10mg Tablet, film coated 1,740,724 L.L
    1
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025